Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis

Vaccine

Volumn 31, Issue 7, 2013, Pages 1057-1064

  Waeckerle Men, Ying ^a   Bruffaerts, Nicolas ^b   Liang, Yuan ^a,e   Jurion, Fabienne ^b   Sander, Peter ^c,d   Kündig, Thomas M ^a   Huygen, Kris ^b   Johansen, Pål ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d Nationales Zentrum fur Mykobakterien   (Switzerland)

^e CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

BCG; Lymph nodes; Mouse model; T cell responses; TB vaccine

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; LYMPH NODE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUBERCULOSIS; VACCINATION; WILD TYPE;

ANIMALS; BCG VACCINE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; INJECTIONS, INTRADERMAL; INJECTIONS, INTRALYMPHATIC; INJECTIONS, SUBCUTANEOUS; LYMPH NODES; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY; VACCINATION;

EID: 84872616132     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.034     Document Type: Article

References (36)

1. WHO Global tuberculosis control 2010 2010, World Health Organization, Geneva.
2. Kwan C.K., Ernst J.D. HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev 2011, 24:351-376.
3. Gandhi N.R., Nunn P., Dheda K., Schaaf H.S., Zignol M., van Soolingen D., et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010, 375:1830-1843.
4. Lin M.Y., Geluk A., Smith S.G., Stewart A.L., Friggen A.H., Franken K.L., et al. Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination. Infect Immun 2007, 75:3523-3530.
5. Potian J.A., Rafi W., Bhatt K., McBride A., Gause W.C., Salgame P. Preexisting helminth infection induces inhibition of innate pulmonary anti-tuberculosis defense by engaging the IL-4 receptor pathway. J Exp Med 2011, 208:1863-1874.
6. Ryan A.A., Nambiar J.K., Wozniak T.M., Roediger B., Shklovskaya E., Britton W.J., et al. Antigen load governs the differential priming of CD8 T cells in response to the bacille Calmette Guerin vaccine or Mycobacterium tuberculosis infection. J Immunol 2009, 182:7172-7177.
7. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet 1996;348:17-24.
8. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994, 271:698-702.
9. Morris S., Kelley C., Howard A., Li Z., Collins F. The immunogenicity of single and combination DNA vaccines against tuberculosis. Vaccine 2000, 18:2155-2163.
10. Walzl G., Ronacher K., Hanekom W., Scriba T.J., Zumla A. Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011, 11:343-354.
11. Cooper A.M. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009, 27:393-422.
12. Stenger S., Hanson D.A., Teitelbaum R., Dewan P., Niazi K.R., Froelich C.J., et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998, 282:121-125.
13. Foulds K.E., Wu C.Y., Seder R.A. Th1 memory: implications for vaccine development. Immunol Rev 2006, 211:58-66.
14. Brennan M.J., Thole J. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis (Edinb) 2012, 92:S6-S13.
15. Kaufmann S.H., Hussey G., Lambert P.H. New vaccines for tuberculosis. Lancet 2010, 375:2110-2119.
16. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004, 10:1240-1244.
17. Festjens N., Bogaert P., Batni A., Houthuys E., Plets E., Vanderschaeghe D., et al. Disruption of the SapM locus in Mycobacterium bovis BCG improves its protective efficacy as a vaccine against M. tuberculosis. EMBO Mol Med 2011, 3:222-234.
18. Kaufmann S.H. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect Dis 2011, 11:633-640.
19. Bastos R.G., Borsuk S., Seixas F.K., Dellagostin O.A. Recombinant Mycobacterium bovis BCG. Vaccine 2009, 27:6495-6503.
20. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser Eddine A., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 2005, 115:2472-2479.
21. Johansen P., Fettelschoss A., Amstutz B., Selchow P., Waeckerle-Men Y., Keller P., et al. Relief from Zmp1-mediated arrest of phagosome maturation is associated with facilitated presentation and enhanced immunogenicity of mycobacterial antigens. Clin Vaccine Immunol 2011, 18:907-913.
22. Master S.S., Rampini S.K., Davis A.S., Keller C., Ehlers S., Springer B., et al. Mycobacterium tuberculosis prevents inflammasome activation. Cell Host Microbe 2008, 3:224-232.
23. Johansen P., Haffner A.C., Koch F., Zepter K., Erdmann I., Maloy K., et al. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J Immunol 2005, 35:568-574.
24. Korf H., Vander Beken S., Romano M., Steffensen K.R., Stijlemans B., Gustafsson J.A., et al. Liver X receptors contribute to the protective immune response against Mycobacterium tuberculosis in mice. J Clin Invest 2009, 119:1626-1637.
25. Romano M., Roupie V., Wang X.M., Denis O., Jurion F., Adnet P.Y., et al. Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3. Immunology 2006, 118:321-332.
26. Hiraishi Y., Nandakumar S., Choi S.O., Lee J.W., Kim Y.C., Posey J.E., et al. Bacillus Calmette-Guerin vaccination using a microneedle patch. Vaccine 2011, 29:2626-2636.
27. Badell E., Nicolle F., Clark S., Majlessi L., Boudou F., Martino A., et al. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells. Vaccine 2009, 27:28-37.
28. Randolph G.J., Angeli V., Swartz M.A. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol 2005, 5:617-628.
29. Gray D. A role for antigen in the maintenance of immunological memory. Nat Rev Immunol 2002, 2:60-65.
30. Huppa J.B., Gleimer M., Sumen C., Continuous Davis M.M. T cell receptor signaling required for synapse maintenance and full effector potential. Nat Immunol 2003, 4:749-755.
31. Ottenhoff T.H., Verreck F.A., Hoeve M.A., van de Vosse E. Control of human host immunity to mycobacteria. Tuberculosis (Edinb) 2005, 85:53-64.
32. Lawn S.D., Myer L., Edwards D., Bekker L.G., Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009, 23:1717-1725.
33. Murray R.A., Mansoor N., Harbacheuski R., Soler J., Davids V., Soares A., et al. Bacillus Calmette Guerin vaccination of human newborns induces a specific, functional CD8+ T cell response. J Immunol 2006, 177:5647-5651.
34. Villarreal-Ramos B., McAulay M., Chance V., Martin M., Morgan J., Howard C.J. Investigation of the role of CD8+ T cells in bovine tuberculosis in vivo. Infect Immun 2003, 71:4297-4303.
35. Bannister C., Bennett L., Carville A., Azzopardi P. Evidence behind the WHO guidelines: hospital care for children: what is the evidence that BCG vaccination should not be used in HIV-infected children. J Trop Pediatr 2009, 55:78-82.
36. Tullius M.V., Harth G., Maslesa-Galic S., Dillon B.J., Horwitz M.A. A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG. Infect Immun 2008, 76:5200-5214.